[1]
|
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, VARIANTS COUMARIN RESISTANCE LEU-29; ALA-45; GLY-58 AND ARG-128, AND VARIANT VKCFD2 TRP-98.
TISSUE=Kidney;
DOI=10.1038/nature02214; PubMed=14765194 [NCBI, ExPASy, EBI, Israel, Japan]
Rost S.,
Fregin A.,
Ivaskevicius V.,
Conzelmann E.,
Hoertnagel K.,
Pelz H.-J.,
Lappegard K.,
Seifried E.,
Scharrer I.,
Tuddenham E.G.D.,
Mueller C.R.,
Strom T.M.,
Oldenburg J.;
"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.";
Nature 427:537-541(2004).
|
[2]
|
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
DOI=10.1038/nature02254; PubMed=14765195 [NCBI, ExPASy, EBI, Israel, Japan]
Li T.,
Chang C.-Y.,
Jin D.-Y.,
Lin P.-J.,
Khvorova A.,
Stafford D.W.;
"Identification of the gene for vitamin K epoxide reductase.";
Nature 427:541-544(2004).
|
[3]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
TISSUE=Aorta;
Liu B.,
Qin B.M.,
Sheng H.,
Zhao B.,
Liu Y.Q.,
Wang X.Y.,
Zhang Q.,
Song L.,
Lu H.,
Xu H.S.,
Zheng W.Y.,
Gong J.,
Wang Y.B.,
Liu Y.Q.,
Zhang C.N.,
Shi Y.,
Wang W.,
Zhang Z.,
Yang X., ![]()
Han Y.,
Chen J.Z.,
Liu B.H.,
Hui R.T.;
Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
|
[4]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Rieder M.J.,
Daniels R.L.,
da Ponte S.H.,
Hastings N.C.,
Ahearn M.O.,
Rajkumar N.,
Yi Q.,
Nickerson D.A.;
"SeattleSNPs. NHLBI HL66682 program for genomic applications, UW-FHCRC, Seattle, WA (URL: http://pga.gs.washington.edu).";
Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
|
[5]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
TISSUE=Lung;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
|
[6]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 44-163 (ISOFORM 1).
DOI=10.1101/gr.1293003; PubMed=12975309 [NCBI, ExPASy, EBI, Israel, Japan]
Clark H.F.,
Gurney A.L.,
Abaya E.,
Baker K.,
Baldwin D.T.,
Brush J.,
Chen J.,
Chow B.,
Chui C.,
Crowley C.,
Currell B.,
Deuel B.,
Dowd P.,
Eaton D.,
Foster J.S.,
Grimaldi C.,
Gu Q.,
Hass P.E.,
Heldens S., ![]()
Huang A.,
Kim H.S.,
Klimowski L.,
Jin Y.,
Johnson S.,
Lee J.,
Lewis L.,
Liao D.,
Mark M.R.,
Robbie E.,
Sanchez C.,
Schoenfeld J.,
Seshagiri S.,
Simmons L.,
Singh J.,
Smith V.,
Stinson J.,
Vagts A.,
Vandlen R.L.,
Watanabe C.,
Wieand D.,
Woods K.,
Xie M.-H.,
Yansura D.G.,
Yi S.,
Yu G.,
Yuan J.,
Zhang M.,
Zhang Z.,
Goddard A.D.,
Wood W.I.,
Godowski P.J.,
Gray A.M.;
"The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.";
Genome Res. 13:2265-2270(2003).
|
[7]
|
POTENTIAL REDOX ACTIVE SITE.
DOI=10.1016/j.tibs.2004.04.004; PubMed=15276181 [NCBI, ExPASy, EBI, Israel, Japan]
Goodstadt L.,
Ponting C.P.;
"Vitamin K epoxide reductase: homology, active site and catalytic mechanism.";
Trends Biochem. Sci. 29:289-292(2004).
|
[8]
|
TOPOLOGY.
DOI=10.1074/jbc.M500765200; PubMed=15716279 [NCBI, ExPASy, EBI, Israel, Japan]
Tie J.-K.,
Nicchitta C.,
von Heijne G.,
Stafford D.W.;
"Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation.";
J. Biol. Chem. 280:16410-16416(2005).
|
[9]
|
MUTAGENESIS, AND POTENTIAL REDOX ACTIVE SITE.
PubMed=16270630 [NCBI, ExPASy, EBI, Israel, Japan]
Rost S.,
Fregin A.,
Hunerberg M.,
Bevans C.G.,
Muller C.R.,
Oldenburg J.;
"Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin.";
Thromb. Haemost. 94:780-786(2005).
|
|
ExPASy Home page
CBR Canada
